CIAM
HUMA icon

Caitong International Asset Management’s Humacyte HUMA Stock Holding History

Caitong International Asset Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-70,414
Closed -$67.6K – 2803
2025
Q4 		$67.6K Buy
70,414
+62,931
+841% +$89.1K 0.02% 587
2025
Q3 		$13K Buy
7,483
+1,488
+25% +$2.92K 0.01% 924
2025
Q2 		$12.5K Buy
5,995
+5,278
+736% +$10.1K 0.01% 645
2025
Q1 		$1.22K Sell
717
-791
-52% -$2.97K ﹤0.01% 1512
2024
Q4 		$7.62K Buy
+1,508
New +$7.46K 0.01% 994

Other funds holding HUMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Caitong International Asset Management's HUMA Position: Q1 2026 in Review

Caitong International Asset Management sold out of Humacyte (HUMA) in Q1 2026, closing a stake of 70,414 shares — an estimated $67.6K sold.

Caitong International Asset Management first reported a position in HUMA in Q4 2024 and held it in 5 quarters. The position peaked at $67.6K in Q4 2025. 159 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Caitong International Asset Management reported no remaining Humacyte position as of Q1 2026 after selling out during the quarter.
  • Caitong International Asset Management sold 70,414 Humacyte shares in Q1 2026, an estimated $67.6K.
  • Caitong International Asset Management first reported a position in Humacyte in Q4 2024 and held it in 5 quarters.
  • Caitong International Asset Management's Humacyte position peaked at $67.6K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.